Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

Gilead Sciences Inc's GILD unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL).
Yescarta boosted event-free survival (EFS) over a standard of care regimen of physicians’-choice therapy followed by high-dose chemo plus a stem cell transplant.
At a two-year check-in, patients dosed with Yescarta posted a 60% relative increase in EFS over the standard of care.
The study also hit its secondary objective response rate endpoint, but overall survival data were still too immature to judge, Kite said.
The safety results from the study, which enrolled 359 patients across 77 treatment centers, were consistent with prior trials.
6% of patients experienced grade 3 or higher cytokine release syndrome.
Kite plans to submit the data for regulatory approval in the US and EU later this year and present updated data at an upcoming medical meeting.
Price Action: GILD shares are up 0.87% at $68.47 during the market session on the last check Monday.